Souhaitez-vous accéder aux communiqués récents ?

MKIs uniquely block multiple receptor tyrosine kinases (RTKs) simultaneously, addressing the inflammatory, vascular, and fibrotic causes of serious, underserved front-of-the-eye diseases  Lead MKI...

PRESS RELEASE Courbevoie, France – April 22, 2026 A steady organic revenue growth in the first quarter 2026; An evolving macro-environment and a transitioning portfolio mix; Updated 2026 outlook...

First Quarter 2026 Highlights Net income of $24.1 million, or basic earnings per common share of $35.91 and diluted earnings per common share of $35.34; diluted earnings per common share up 7.6%...

WILMETTE, Ill., April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments...

FY 2025/26 order intake and sales delivered as planned Record order intake1 of €27.6 billion, book-to-bill ratio1 of 1.4 and backlog of >€100 billionReported sales1 up 4%, equivalent to 7% on an...

SAN FRANCISCO, April 15, 2026 (GLOBE NEWSWIRE) -- Following its prior announcement that it has entered into a definitive agreement to sell the Allbirds brand and footwear assets to American Exchange...

Revenues of INR 44,877 Million. EBITDA of INR 9,871 Million. Loss for the year INR 1,366 Million. CHENNAI, India, April 13, 2026 (GLOBE NEWSWIRE) -- DETAILS OF EARNING CALL        April...

41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD Reduction Occurred Rapidly Following Cema-Cel Treatment...

Austin, United States, April 10, 2026 (GLOBE NEWSWIRE) -- As per the SNS Insider report the Inhaled Nitric Oxide Market size is valued at USD 1.02 Billion in 2025 and is projected to reach USD 2.01...

Purchase signals growing international demand for counter-UAS capabilities as public safety agencies seek non-lethal response options for modern threats.